DSG1 and acquired polycythemia vera: Janus kinases (JAK) 1 and 3 inhibitors (tofacinib) may also be used as adjuvants in refractory PV, even as a topical treatment as they suppress the activation of Dsg-specific Tfh cells and their influence on B cells phenotype and function [103,109].